VAERS reports by lot

Pfizer RSV lot HF5012: VAERS reports

21 VAERS reports list lot HF5012 as a Pfizer RSV vaccine, received between 2023-11-25 and 2024-05-09. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
21
Reports
14%
Marked serious
0
With a death outcome
7
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Neurological1926%
General / Systemic (non-local)1419%
Cardiac / Cardiovascular1014%
Injection-site / Local reaction811%
Dermatological (non-injection-site)710%
Respiratory46%
Gastrointestinal34%
Musculoskeletal34%
Allergic / Anaphylactic23%
Thrombotic / Hematological11%
Autoimmune / Immune-mediated11%

Where reports came from

U.S. state of the reporter, where given (top 12).

Ohio2
Iowa2
Oregon2
Minnesota2
South Dakota2
Virginia1
Idaho1
Connecticut1
Illinois1
Wisconsin1
Kansas1
Massachusetts1

Reports by month received

2023-111
2023-129
2024-017
2024-021
2024-031
2024-041
2024-051

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.